Australia markets closed

Botanix Pharmaceuticals Limited (BOT.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.1000+0.0030 (+3.09%)
At close: 04:10PM AEDT
Full screen
Previous close0.0970
Bid0.1000 x 38103100
Ask0.1050 x 63288200
Day's range0.0970 - 0.1050
52-week range0.0520 - 0.1150
Avg. volume2,145,215
Market cap118.748M
Beta (5Y monthly)1.89
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors advancing through early preclinical stage studies BOULDER, Colo., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developin

  • GlobeNewswire

    Brickell Biotech Announces Sale of Sofpironium Bromide to Botanix Pharmaceuticals

    Deal includes up to $9 million in upfront and potential near-term regulatory milestone payments, $168 million in potential future regulatory and sales milestone payments, plus tiered earn out payments on net sales to Brickell Sale reflects Brickell’s strategic shift into the immunology and inflammation fields; proceeds will be used to advance Company’s pipeline of recently acquired novel therapies BOULDER, Colo., May 03, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell” o